LEXEO THERAPEUTICS INC (LXEO) Stock News
NASDAQ:LXEO - Nasdaq - US52886X1072 - Common Stock - Currency: USD
LXEO Latest News, Press Relases and Analysis
Which stocks are moving on Wednesday?
Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session.
Which stocks are moving on Monday?
Here are the top movers in Monday's session, showcasing the stocks with significant price changes.
Keep an eye on the top gainers and losers in Monday's session.
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.
Monday's session: gap up and gap down stocks
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study...
Pharma Frenzy: Volatility Ignites Biotech Sector
Two biotech companies have surged on recent developments, illustrating biotech's volatility and prompting investors to evaluate potential long-term value.
Mentions: TNXP
Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's The Big Draw?
The company reported an adjusted Q4 loss of $0.78 per share, beating expectations for a $0.81 loss.
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights...
Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference...
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer...
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results...
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's...
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference...
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
Lexeo Therapeutics to Participate in Upcoming Investor Conferences - September 2024...
LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024
LXEO stock results show that Lexeo Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lexeo Therapeutics (NASDAQ:LXEO) just reported results for the second quarter o...
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no...
Why Top 4% Biotech Stock Lexeo Therapeutics Just Gave Up A Breakout
The company is in the early stages of testing a gene therapy for the heart complications of a genetic disease.
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline ...
Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024
NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering...
Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors ...
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights...